All News

. Prescribers should know that the FDA has updated its warnings to say that fluoroquinolones should not be prescribed to patients who have other treatment options for acute bacterial sinusitis, acute exacerbation of chronic bronchitis, and uncomplicated urinary tract infections

Other new products discussed in this article include a surgical training model, devices designed to improve prostate biopsy accuracy, an updated label and more.

The genomic profiling tool distinguishes among the dominant three malignant and one benign renal cancer subtypes.

Two late-stage immunotherapy drugs for the treatment of urothelial carcinoma reach regulatory, research milestones.

In this exclusive interview, Andy Slavitt, acting administrator for the Centers for Medicare & Medicaid Services, discusses alternative payment models, outlines what resources are available for practices, and provides an overview of the three options practices have for participation in the Quality Payment Program.

Testosterone therapy in hypogonadal men with prostate cancer who have had definitive treatment and in those on surveillance appears to be safe, according to a new study.

An examination of data involving more than 63,000 PSA tests ordered by primary care physicians reveals some surprising findings.

A recent study shows children born to high-status parents have a higher incidence rate of developing prostate and other cancers in later life.

A team from Roswell Park Cancer Institute has developed and validated a quality assessment tool based on prospectively collected data on robot-assisted cystectomy.

Two days of discussions at the Sept. 7 and 8 meetings of the Medicare Payment Advisory Commission highlighted the difficulties and complexities that will face policymakers as they consider solutions to the financial crisis facing Medicare.

In this article, the the most recent installment in an ongoing series, Robert A. Dowling, MD, summarizes his first impressions of the MACRA final rule and what it means for urologists.

Although a recent study of testosterone therapy does not fulfill the need for large-scale, randomized, controlled studies of the treatment, “it is very informative in several ways,” writes Arthur L. Burnett, II, MD, MBA.

As we approach the end of the year, take the necessary time to review your financial planning strategies. A lot can happen in a year.

Long-term testosterone therapy in hypogonadal men improves urinary function and erectile function compared with untreated controls, according to registry data from a single practice.

“I think we’re seeing more younger men coming in with erectile dysfunction, because there’s just a lot more publicity about the issue," one urologist said.

"We strongly recommend that you obtain your practice QRUR regardless of your practice size and learn more about the report," write Ray Painter, MD, and Mark Painter.

Other pipeline developments discussed in this article include the initiation of an intravesical bladder cancer study, a gel treatment for ED that has met its primary endpoint, a patent awarded for the first rechargeable implantable SNM along with some other advancements.

The risk of prostate cancer relapse after radical prostatectomy increases with lengthening delay between diagnosis and surgery. The impact, however, is significant only in high-risk patients, and even in those men, there may be a window of up to 12 months during which it may be relatively safe to postpone surgery, reported researchers from Milan, Italy.

In this interview, Daniel Shoskes, MD, discusses his evaluation of patients with scrotal pain, outlines his use of conservative treatments, and explains surgical approaches and how he decides whether to use them.

As a practicing urologist, it is in your best interest to understand what a spoliation charge means in the state where you practice and the requirements of proof.

Urologist Henry Rosevear, MD, discusses actor Ben Stiller's recent blog post that credits PSA tests for saving his life after he was diagnosed with prostate cancer and the urologic community's surprising reaction to the article.

A new study revealing 91% of very low-risk and 74% of low-risk prostate cancer patients in Sweden choose active surveillance should be a benchmark for the use of the management strategy in the U.S. and elsewhere in the world, the study’s authors say.

Through UROPAC - Urology's Advocate on Capitol Hill, the AACU recently redoubled its commitment to connect urologists with their representatives and has found early success in doing so.

Bilateral replacement of the uterosacral ligaments with a polyvinylidene fluoride (PVDF) mesh (DynaMesh, FEG Textiltechnik mbH) is more effective than medical treatment with solifenacin (Vesicare) for achieving continence in women with urgency urinary incontinence (UUI) associated with only minor pelvic organ prolapse, according to the interim results of a prospective, randomized, crossover clinical trial.

Hypogonadism in men undergoing artificial urinary sphincter (AUS) implantation significantly increases the risk of cuff erosion, according to the results of a study presented by urologists from UT Southwestern Medical Center, Dallas.

Nearly 100% of patients with clinically localized prostate cancer, detected by PSA testing, survive at an average 10 years’ follow-up, regardless of whether they had active monitoring, radical prostatectomy, or radiotherapy, according to new study results.